How to conduct research of rare autoimmune diseases

References

• Terao C, Yamada R, Mimori T, Yamamoto K, Sumida T. A nationwide study of SLE in Japanese identified subgroups of patients with clear signs patterns and associations between signs and age or sex. Lupus. 2014;23:1435–42.
   PubMed Web of Science ®Google Scholar
• Verma DK, Tripathy NK, Verma NS, Tiwari S. Interleukin 12 in Takayasu's arteritis: plasma concentrations and relationship with disease activity. J Rheumatol. 2005;32:2361–3.
   PubMed Web of Science ®Google Scholar
• Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376–81.
   PubMed Web of Science ®Google Scholar
• Terao C, Ohmura K, Katayama M, Takahashi M, Kokubo M, Diop G, et al. Myelin basic protein as a novel genetic risk factor in rheumatoid arthritis – a genome-wide study combined with immunological analyses. PLoS One. 2011;6:e20457.
   PubMed Web of Science ®Google Scholar
• Terao C, Yamada R, Ohmura K, Takahashi M, Kawaguchi T, Kochi Y, et al. The human AIRE gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. Hum Mol Genet. 2011;20:2680–5.
   PubMed Web of Science ®Google Scholar
• Terao C, Yoshifuji H, Mimori T. Recent advances in Takayasu arteritis. Int J Rheum Dis. 2014;17:238–47.
   PubMed Web of Science ®Google Scholar
• Terao C, Yoshifuji H, Ohmura K, Murakami K, Kawabata D, Yurugi K, et al. Association of Takayasu arteritis with HLA-B 67:01 and two amino acids in HLA-B protein. Rheumatology (Oxford). 2013;52:1769–74.
   PubMed Web of Science ®Google Scholar
• Terao C, Yoshifuji H, Kimura A, Matsumura T, Ohmura K, Takahashi M, et al. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Am J Hum Genet. 2013;93:289–97.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Yoshifuji H, Shimizu M, Kitagori K, Murakami K, Nakashima R, et al. A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production. Arthritis Res Ther. 2017;19:197.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Ishii T, Nakamura K, Shirai T, Fujii H, Saito S, Harigae H. Ulcerative colitis is not a rare complication of Takayasu arteritis. Mod Rheumatol. 2014;24:372–3.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Tanabe K, Sugamori T, Sato M, Kitamura J, Sato H, et al. Association between Takayasu arteritis and ulcerative colitis – case report and review of serological HLA analysis. Med Sci Monit. 2011;17:CS81–4.
   PubMed Web of Science ®Google Scholar
• Gecse K, Ruzsa Z, Nagy F, Wittmann T, Molnar T. Successful infliximab treatment in a patient with Takayasu arteritis associated with ulcerative colitis or migration does not override genetics. Inflamm Bowel Dis. 2011;17:E69–70.
   PubMedGoogle Scholar
• Bansal R, Aggarwal P, Handa R, Biswas A, Bandhu S, Wali JP. Ulcerative colitis associated with Takayasu arteritis. Int J Cardiol. 2003;88:91–3.
   PubMed Web of Science ®Google Scholar
• Terao C, Matsumura T, Yoshifuji H, Kirino Y, Maejima Y, Nakaoka Y, et al. Takayasu arteritis and ulcerative colitis–high concurrence ratio and genetic overlap. Arthritis Rheumatol. 2015;67(8):2226–32.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367:1519–28.
   PubMed Web of Science ®Google Scholar
• Yeilding N, Szapary P, Brodmerkel C, Benson J, Plotnick M, Zhou H, et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives – an update. Ann N Y Acad Sci. 2012;1263:1–12.
   PubMed Web of Science ®Google Scholar
• Terao C, Yoshifuji H, Nakajima T, Yukawa N, Matsuda F, Mimori T. Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application. Scand J Rheumatol. 2016;45:80–2.
   PubMed Web of Science ®Google Scholar
• Puechal X, Terrier B, Mouthon L, Costedoat-Chalumeau N, Guillevin L, Le Jeunne C. Relapsing polychondritis. Joint Bone Spine. 2014;81:118–24.
   PubMed Web of Science ®Google Scholar
• Terao C, Yoshifuji H, Yamano Y, Kojima H, Yurugi K, Miura Y, et al. Genotyping of relapsing polychondritis identified novel susceptibility HLA alleles and distinct genetic characteristics from other rheumatic diseases. Rheumatology (Oxford). 2016;55:1686–92.
   PubMed Web of Science ®Google Scholar
• Hu X, Deutsch AJ, Lenz TL, Onengut-Gumuscu S, Han B, Chen WM, et al. Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk. Nat Genet. 2015;47:898–905.
   PubMed Web of Science ®Google Scholar
• Shimane K, Kochi Y, Suzuki A, Okada Y, Ishii T, Horita T, et al. An association analysis of HLA-DRB1 with systemic lupus erythematosus and rheumatoid arthritis in a Japanese population: effects of *09:01 allele on disease phenotypes. Rheumatology (Oxford). 2013;52:1172–82.
   PubMed Web of Science ®Google Scholar
• de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287–96.
   PubMed Web of Science ®Google Scholar
• Firestein GS, Gruber HE, Weisman MH, Zvaifler NJ, Barber J, O'Duffy JD. Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondritis and Behcet's disease. Am J Med. 1985;79:65–72.
   PubMed Web of Science ®Google Scholar
• Terao C, Kawaguchi T, Dieude P, Varga J, Kuwana M, Hudson M, et al. Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. Ann Rheum Dis. 2017;76:1150–8.
   PubMed Web of Science ®Google Scholar